AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions of the claims and listing of the claims in the application:

1. **(Previously Presented)** A compound of formula I:



(I)

wherein:

X is $CHC(R^{13}Y'Y)$ or $CR^{6'}R^{6}$;

R^{2}, $R^{4'}$, $R^{4"}$, $R^{7'}$ and $R^{7"}$ are each hydrogen, alkyl, alkenyl, alkynyl, alkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl, alkylamino, arylalkyl, aryl, heterocyclic, heteroaromatic or a prodrug moiety;

$R^{2'}$, R^{3}, R^{10}, R^{11} and R^{12} are each hydrogen or a pro-drug moiety;

R^{4} is $NR^{4'}R^{4"}$, alkyl, alkenyl, alkynyl, aryl, hydroxyl, halogen, or hydrogen;

R^{5} is hydroxyl, hydrogen, thiol, alkanoyl, aroyl, alkaroyl, aryl, heteroaromatic, alkyl, alkenyl, alkynyl, alkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl, alkylamino, arylalkyl, alkyl carbonyloxy, or aryl carbonyloxy;

R^{6} and $R^{6'}$ are independently hydrogen, methylene, absent, hydroxyl, halogen, thiol, alkyl, alkenyl, alkynyl, aryl, alkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl, alkylamino, or an arylalkyl;

R^{8} is hydrogen, hydroxyl, halogen, thiol, alkyl, alkenyl, alkynyl, aryl, alkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl, alkylamino, or an arylalkyl;

R^{9} is aminomethyl;

R^{13} is hydrogen, hydroxy, alkyl, alkenyl, alkynyl, alkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl, alkylamino, or an arylalkyl;

Y' and Y are each independently hydrogen, halogen, hydroxyl, cyano, sulfhydryl, amino, alkyl, alkenyl, alkynyl, alkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl, alkylamino, or an arylalkyl, and pharmaceutically acceptable salts, esters and prodrugs thereof.

2. **(Original)** The compound of claim 1, wherein R^{4} is $NR^{4'}R^{4"}$; X is $CR^{6}R^{6'}$; R^{2}, $R^{2'}$, R^{5}, R^{6}, $R^{6'}$, R^{8}, R^{9}, R^{10}, R^{11}, and R^{12} are each hydrogen; and, $R^{4'}$, $R^{4"}$, $R^{7'}$, and $R^{7"}$ are each lower alkyl.

3. **(Original)** The compound of claim 2, wherein $R^{4'}$, $R^{4''}$, $R^{7'}$, and $R^{7''}$ are each methyl.

4. **(Cancelled).**

5. **(Previously Presented)** The compound of claim 3, wherein said aminomethyl is substituted with an alkyl group.

6. **(Original)** The compound of claim 5, wherein said alkyl group is methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, nonyl, or decyl.

7. **(Original)** The compound of claim 6, wherein said alkyl group is a branched chain alkyl group.

8. **(Original)** The compound of claim 5, wherein said alkyl group is n-pentyl.

9. **(Original)** The compound of claim 5, wherein said alkyl group has six carbon atoms or fewer.

10. **(Original)** The compound of claim 5, wherein said alkyl group is unsubstituted.

11. **(Original)** The compound of claim 5, wherein said alkyl group is substituted.

12. **(Original)** The compound of claim 11, wherein said alkyl group is substituted with alkenyl, alkynyl, halogen, hydroxyl, alkylcarbonyloxy, arylcarbonyloxy, alkoxycarbonyloxy, aryloxycarbonyloxy, carboxylate, alkylcarbonyl, arylcarbonyl, alkoxycarbonyl, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, alkylthiocarbonyl, alkoxyl, phosphate, phosphonato, phosphinato, cyano, amino, acylamino, amidino, imino, sulfhydryl, alkylthio, arylthio, thiocarboxylate, sulfates, alkylsulfinyl, sulfonato, sulfamoyl, sulfonamido, nitro, trifluoromethyl, cyano, azido, heterocyclyl, alkylaryl, or an aromatic or heteroaromatic moiety.

13. **(Previously Presented)** The compound of claim 3, wherein said aminomethyl is substituted with two alkyl groups.

14. **(Previously Presented)** The compound of claim 5, wherein said compound is:

 or a pharmaceutically acceptable salt, ester or prodrug thereof.

15. **(Previously Presented)** The compound of claim 1, wherein said compound is



or a pharmaceutically acceptable salt, ester or prodrug thereof.

16-37. **(Cancelled)**

38. **(Previously Pending)** A method for treating a bacterial infection in a mammal, comprising administering to said mammal a compound of claim 1, such that said mammal is treated.

39. **(Cancelled).**

40. **(Previously Presented)** The method of claim 38, wherein said bacterial infection is associated with gram positive bacteria.

41. **(Previously Presented)** The method of claim 38, wherein said bacterial infection is associated with gram negative bacteria.

42. **(Previously Presented)** The method of claim 38, wherein said bacterial infection is associated with *E. coli.*

43. **(Previously Presented)** The method of claim 38, wherein said bacterial infection is associated with *S. aureus.*

44. **(Previously Presented)** The method of claim 38, wherein said bacterial infection is associated with *E. faecalis.*

45. **(Cancelled)**

46. **(Previously Presented)** The method of any one of claims 38, or 40-44, wherein said compound is administered with a pharmaceutically acceptable carrier.

47. **(Previously Presented)** The method of any one of claims 38, or 40-44, wherein said subject is a human.

48. **(Previously Presented)** A pharmaceutical composition comprising a therapeutically effective amount of a compound of claim 1 and a pharmaceutically acceptable carrier.

49. **(Previously Presented)** The compound of claim 5, wherein said compound is:



, or a pharmaceutically acceptable salt, ester or prodrug thereof.

50. **(Previously Presented)** The compound of claim 5, wherein said compound is:



, or a pharmaceutically acceptable salt, ester or prodrug thereof.

51. **(Previously Presented)** The compound of claim 5, wherein said compound is:



, or a pharmaceutically acceptable salt, ester or prodrug thereof.

52. **(Previously Presented)** The compound of claim 5, wherein said compound is:



, or a pharmaceutically acceptable salt, ester or prodrug thereof.

53. **(Previously Presented)** The compound of claim 5, wherein said compound is:



, or a pharmaceutically acceptable salt, ester or prodrug thereof.

54. **(Previously Presented)** The compound of claim 5, wherein said compound is:



, or a pharmaceutically acceptable salt, ester or prodrug thereof.

55. **(Previously Presented)** The compound of claim 5, wherein said compound is:



, or a pharmaceutically acceptable salt, ester or prodrug thereof.

56.-82. **(Cancelled).**

83. **(Previously Presented)** A method for treating a bacterial infection in a mammal, comprising administering to said mammal a compound of claim 14, such that said mammal is treated.

84. **(Previously Presented)** A method for treating a bacterial infection in a mammal, comprising administering to said mammal a compound of claim 15, such that said mammal is treated.

85. **(Previously Presented)** The method of claim 84, wherein said bacterial infection is associated with gram positive bacteria.

86. **(Previously Presented)** The method of claim 84, wherein said bacterial infection is associated with gram negative bacteria.

87. **(Previously Presented)** The method of claim 84, wherein said bacterial infection is associated with *E. coli.*

88. **(Previously Presented)** The method of claim 84, wherein said bacterial infection is associated with *S. aureus.*

89. **(Previously Presented)** The method of claim 84, wherein said bacterial infection is associated with *E. faecalis.*

90. **(Previously Presented)** The method of any one of claims 84-89, wherein said compound is administered with a pharmaceutically acceptable carrier.

91. **(Previously Presented)** The method of any one of claims 84-89, wherein said mammal is a human.

92. **(Cancelled).**

93. **(Previously Presented)** A method for treating a bacterial infection in a mammal, comprising administering to said mammal a compound of claim 49, such that said mammal is treated.

94. **(Previously Presented)** A method for treating a bacterial infection in a mammal, comprising administering to said mammal a compound of claim 50, such that said mammal is treated.

95. **(Previously Presented)** A method for treating a bacterial infection in a mammal, comprising administering to said mammal a compound of claim 51, such that said mammal is treated.

96. **(Previously Presented)** A method for treating a bacterial infection in a mammal, comprising administering to said mammal a compound of claim 52, such that said mammal is treated.

97. **(Previously Presented)** A method for treating a bacterial infection in a mammal, comprising administering to said mammal a compound of claim 53, such that said mammal is treated.

98. **(Previously Presented)** A method for treating a bacterial infection in a mammal, comprising administering to said mammal a compound of claim 54, such that said mammal is treated.

99. **(Previously Presented)** A method for treating a bacterial infection in a mammal, comprising administering to said mammal a compound of claim 55, such that said mammal is treated.

100-126 (**Cancelled).**

127. **(Previously Presented)** A pharmaceutical composition comprising a therapeutically effective amount of a compound of claim 14 and a pharmaceutically acceptable carrier.

128. **(Previously Presented)** A pharmaceutical composition comprising a therapeutically effective amount of a compound of claim 15 and a pharmaceutically acceptable carrier.

129. **(Cancelled)**.

130. **(Previously Presented)** A pharmaceutical composition comprising a therapeutically effective amount of a compound of claim 49 and a pharmaceutically acceptable carrier.

131. **(Previously Presented)** A pharmaceutical composition comprising a therapeutically effective amount of a compound of claim 50 and a pharmaceutically acceptable carrier.

132. **(Previously Presented)** A pharmaceutical composition comprising a therapeutically effective amount of a compound of claim 51 and a pharmaceutically acceptable carrier.

133. **(Previously Presented)** A pharmaceutical composition comprising a therapeutically effective amount of a compound of claim 52 and a pharmaceutically acceptable carrier.

134. **(Previously Presented)** A pharmaceutical composition comprising a therapeutically effective amount of a compound of claim 53 and a pharmaceutically acceptable carrier.

135. **(Previously Presented)** A pharmaceutical composition comprising a therapeutically effective amount of a compound of claim 54 and a pharmaceutically acceptable carrier.

136. **(Previously Presented)** A pharmaceutical composition comprising a therapeutically effective amount of a compound of claim 55 and a pharmaceutically acceptable carrier.

137.-163 **(Cancelled).**

164. **(Previously Presented)** A compound of the formula:



or a pharmaceutically acceptable salt thereof.

165. **(Previously Presented)** A pharmaceutical composition comprising a therapeutically effective amount of a compound of claim 164 and a pharmaceutically acceptable carrier.

166. **(Previously Presented)** A method for treating a bacterial infection in a mammal, comprising administering to said mammal a compound of claim 164, such that said mammal is treated.

167. **(Currently Amended)** The method of claim 166~~167~~, wherein said bacterial infection is associated with gram positive bacteria.

168. **(Currently Amended)** The method of claim 166~~167~~, wherein said bacterial infection is associated with gram negative bacteria.

169. **(Currently Amended)** The method of claim 166~~167~~, wherein said bacterial infection is associated with *E. coli.*

170. **(Currently Amended)** The method of claim 166~~167~~, wherein said bacterial infection is associated with *S. aureus*.

171. **(Currently Amended)** The method of claim 166~~167~~, wherein said bacterial infection is associated with *E. faecalis.*

172. **(Previously Presented)** The method of any one of claims 167-171, wherein said compound is administered with a pharmaceutically acceptable carrier.

173. **(Previously Presented)** The method of any one of claims 167-171, wherein said mammal is a human.

174. **(Currently Amended)** A compound selected from the group consisting of:





or a pharmaceutically acceptable salt thereof.

175. **(Previously Presented)** The compound of claim 174, wherein said compound is:



.

176. **(Previously Presented)** The compound of claim 174, wherein said compound is:



.

177. **(Previously Presented)** The compound of claim 174, wherein said compound is:



178. **(Previously Presented)** The compound of claim 174, wherein said compound is:



179. **(Previously Presented)** The compound of claim 174, wherein said compound is:



180. **(Previously Presented)** The compound of claim 174, wherein said compound is:



181. **(Previously Presented)** The compound of claim 174, wherein said compound is:



182.-210. (**Cancelled).**

211. **(Previously Presented)** A method for treating a bacterial infection in a mammal, comprising administering to said mammal a compound of claim 175, such that said mammal is treated.

212. **(Previously Presented)** A method for treating a bacterial infection in a mammal, comprising administering to said mammal a compound of claim 176, such that said mammal is treated.

213. **(Previously Presented)** A method for treating a bacterial infection in a mammal, comprising administering to said mammal a compound of claim 177, such that said mammal is treated.

214. **(Previously Presented)** A method for treating a bacterial infection in a mammal, comprising administering to said mammal a compound of claim 178, such that said mammal is treated.

215. **(Previously Presented)** A method for treating a bacterial infection in a mammal, comprising administering to said mammal a compound of claim 179, such that said mammal is treated.

216. **(Previously Presented)** A method for treating a bacterial infection in a mammal, comprising administering to said mammal a compound of claim 180, such that said mammal is treated.

217. **(Previously Presented)** A method for treating a bacterial infection in a mammal, comprising administering to said mammal a compound of claim 181, such that said mammal is treated.

218.-246. **(Canceled).**

247. **(Previously Presented)** A pharmaceutical composition comprising a therapeutically effective amount of a compound of claim 175 and a pharmaceutically acceptable carrier.

248. **(Previously Presented)** A pharmaceutical composition comprising a therapeutically effective amount of a compound of claim 176 and a pharmaceutically acceptable carrier.

249. **(Previously Presented)** A pharmaceutical composition comprising a therapeutically effective amount of a compound of claim 177 and a pharmaceutically acceptable carrier.

250. **(Previously Presented)** A pharmaceutical composition comprising a therapeutically effective amount of a compound of claim 178 and a pharmaceutically acceptable carrier.

251. **(Previously Presented)** A pharmaceutical composition comprising a therapeutically effective amount of a compound of claim 179 and a pharmaceutically acceptable carrier.

252. **(Previously Presented)** A pharmaceutical composition comprising a therapeutically effective amount of a compound of claim 180 and a pharmaceutically acceptable carrier.

253. **(Previously Presented)** A pharmaceutical composition comprising a therapeutically effective amount of a compound of claim 181 and a pharmaceutically acceptable carrier.

254.-282. (**Cancelled).**